Therajan / participating veterinary oncology centers

Specialty hospital / research center

1 current cancer treatment or research opportunity

About the Therajan EGFR/HER2 vaccine study

Therajan leads a multicenter study of an experimental EGFR/HER2 peptide vaccine for dogs with selected cancers. Enrollment and treatment are handled by the participating veterinary oncology centers listed for the protocol.

Therajan study information →

Who the current listings are forDogs
Cancer types currently listedHemangiosarcoma, Osteosarcoma, Urothelial Carcinoma

Current options at Therajan / participating veterinary oncology centers

Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.

Experimental EGFR/HER2 tumor vaccine

Therajan / participating veterinary oncology centers · USA

Currently enrolling at nine confirmed sites; Chicago, Richmond and Missouri are not enrolling

What is being offered: USDA-regulated EGFR/HER2 peptide-vaccine study led by Therajan. The current Canine Cancer Alliance status page identifies nine locations without a non-enrolling warning: Ventura, Edmonds, Pullman, Salt Lake City, Cleveland, Pittsburgh, Cincinnati, Phoenix and Stamford. Its same roster marks Chicago, Richmond and Columbia, Missouri as currently not enrolling. Stamford was separately confirmed on Veterinary Cancer Concierge Services' current trial page, which provides its intake pathway, eligibility materials and appointment location. Site-specific eligibility, scheduling and costs vary; MedVet restrictions apply only to its hospitals. Bridge also considers pulmonary carcinoma and high-grade mast cell tumor after records review, but those site-only indications are not mapped to the shared protocol record.

Who may qualify: Anticipated survival over 3 months; Standard of care therapy; Histology or long bone osa exception

May not qualify if: Other immunotherapy; Alternative therapy; Other clinical study

Costs / coverage: The investigational vaccine is provided at no charge; site visits, conventional treatment, administration and monitoring may be owner-paid. VCCS publishes a $695 charge for each vaccine appointment plus required testing. Confirm exact site-specific costs before enrollment.

Contact: Hope Veterinary Oncology — 805-626-6551; Bridge Animal Referral Center — 425-697-2272; Washington State University — 509-335-0711; MedVet Clinical Studies — clinicalstudies@medvet.com; MedVet Pittsburgh — oncology.pittsburgh@medvet.com; IVO — 602-841-0626; Veterinary Cancer Concierge Services — info@vetcancerconcierge.com.

Participating locations

  • Hope Veterinary Oncology, 1885 Knoll Drive, Ventura, CA 93003, Ventura, CA
  • Bridge Animal Referral Center, 8401 Main St, Edmonds, WA 98026, Edmonds, WA
  • WSU Veterinary Teaching Hospital, 205 Ott Rd, Pullman, WA 99164
  • MedVet Salt Lake City, 331 W Bearcat Dr, Salt Lake City, UT 84115
  • MedVet Cleveland, 20400 Emerald Pkwy, Cleveland, OH 44135
  • MedVet Pittsburgh, 2810 Washington Rd, McMurray, PA 15317
  • MedVet Cincinnati, 3964 Red Bank Rd, Cincinnati, OH 45227
  • IVO Integrative Veterinary Oncology, 2501 N. 32nd Street, Phoenix, AZ 85008, Phoenix, AZ
  • Veterinary Cancer Concierge Services, 1086 Long Ridge Road, Stamford, CT 06903, Stamford, CT

Official study / enrollment information →

Before you contact the center

A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.

Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.

Check all options for your pet →

Free to use. No registration or paid report.